These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 31422701)

  • 1. Predicting initiation of preventive migraine medications: exploratory study in a large U.S. medical claims database.
    Ford JH; Schroeder K; Buse DC; Joshi S; Gelwicks S; Foster SA; Aurora SK
    Curr Med Res Opin; 2020 Jan; 36(1):51-61. PubMed ID: 31422701
    [No Abstract]   [Full Text] [Related]  

  • 2. Cycling Through Migraine Preventive Treatments: Implications for All-Cause Total Direct Costs and Disease-Specific Costs.
    Ford JH; Schroeder K; Nyhuis AW; Foster SA; Aurora SK
    J Manag Care Spec Pharm; 2019 Jan; 25(1):46-59. PubMed ID: 30044691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States.
    Tepper SJ; Fang J; Zhou L; Shen Y; Vo P; Abdrabboh A; Glassberg MB; Ferraris M
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1157-1170. PubMed ID: 33998825
    [No Abstract]   [Full Text] [Related]  

  • 4. Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study.
    Kawata AK; Shah N; Poon JL; Shaffer S; Sapra S; Wilcox TK; Shah S; Tepper SJ; Dodick DW; Lipton RB
    Headache; 2021 Mar; 61(3):438-454. PubMed ID: 33594686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventive treatment of migraine.
    Silberstein SD
    Rev Neurol Dis; 2005; 2(4):167-75. PubMed ID: 16622394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States.
    Bonafede M; Sapra S; Shah N; Tepper S; Cappell K; Desai P
    Headache; 2018 May; 58(5):700-714. PubMed ID: 29446063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Migraine Prophylaxis and Acute Treatment Patterns Among Commercially Insured Patients in the United States.
    Woolley JM; Bonafede MM; Maiese BA; Lenz RA
    Headache; 2017 Oct; 57(9):1399-1408. PubMed ID: 28842990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 3-year follow-up study of outcomes associated with patterns of traditional acute and preventive migraine treatment: An administrative claims-based cohort study in the United States.
    Joshi S; Spargo A; Hoyt M; Panni T; Viktrup L; Kim G; Hasan A; Liu YY; Zakharyan A
    Headache; 2024; 64(7):796-809. PubMed ID: 38898657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence with migraine prophylaxis in clinical practice.
    Berger A; Bloudek LM; Varon SF; Oster G
    Pain Pract; 2012 Sep; 12(7):541-9. PubMed ID: 22300068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment patterns and predictors of costs among patients with migraine: evidence from the United States medical expenditure panel survey.
    Ford JH; Ye W; Nichols RM; Foster SA; Nelson DR
    J Med Econ; 2019 Sep; 22(9):849-858. PubMed ID: 30977712
    [No Abstract]   [Full Text] [Related]  

  • 11. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II).
    Blumenfeld AM; Bloudek LM; Becker WJ; Buse DC; Varon SF; Maglinte GA; Wilcox TK; Kawata AK; Lipton RB
    Headache; 2013 Apr; 53(4):644-55. PubMed ID: 23458496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological prevention of migraine.
    Rapoport AM
    Clin Neurosci; 1998; 5(1):55-9. PubMed ID: 9523060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to oral migraine-preventive medications among patients with chronic migraine.
    Hepp Z; Dodick DW; Varon SF; Gillard P; Hansen RN; Devine EB
    Cephalalgia; 2015 May; 35(6):478-88. PubMed ID: 25164920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug treatment of migraine: Part II. Preventive therapy.
    Noble SL; Moore KL
    Am Fam Physician; 1997 Dec; 56(9):2279-86. PubMed ID: 9402813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Migraine treatment and healthcare costs: retrospective analysis of the China Health Insurance Research Association (CHIRA) database.
    Yu S; Zhang Y; Yao Y; Cao H
    J Headache Pain; 2020 May; 21(1):53. PubMed ID: 32404048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of onabotulinumtoxinA versus oral migraine prophylactic medications on headache-related resource utilization in the management of chronic migraine: Retrospective analysis of a US-based insurance claims database.
    Hepp Z; Rosen NL; Gillard PG; Varon SF; Mathew N; Dodick DW
    Cephalalgia; 2016 Aug; 36(9):862-74. PubMed ID: 26692400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Migraine preventive medication reduces resource utilization.
    Silberstein SD; Winner PK; Chmiel JJ
    Headache; 2003 Mar; 43(3):171-8. PubMed ID: 12603635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Trends in Characteristics of Patients with Migraine Newly Initiated on Erenumab in the USA: A Retrospective Analysis.
    Fang J; Korrer S; Johnson JC; Cheadle MA; Shah R; Ferraris ML; Lopez-Lopez C
    Adv Ther; 2021 Jun; 38(6):2921-2934. PubMed ID: 33763828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The American Registry for Migraine Research: Research Methods and Baseline Data for an Initial Patient Cohort.
    Schwedt TJ; Digre K; Tepper SJ; Spare NM; Ailani J; Birlea M; Burish M; Mechtler L; Gottschalk C; Quinn AM; McGillicuddy L; Bance L; Dumkrieger G; Chong CD; Dodick DW
    Headache; 2020 Feb; 60(2):337-347. PubMed ID: 31755111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare costs and resource utilization in patients with migraine treated with erenumab: A retrospective, non-interventional study using claims data from the United States.
    Tepper SJ; Schwedt TJ; Vo P; Thompson J; Joshi P; Abdrabboh A; Ferraris M; Tiwari S
    Headache; 2023; 63(10):1423-1436. PubMed ID: 37655551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.